Biofrontera (NASDAQ:BFRI) Releases Earnings Results, Misses Expectations By $0.29 EPS

Biofrontera (NASDAQ:BFRI) issued its earnings results on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29), FiscalAI reports. The firm had revenue of $10.08 million during the quarter, compared to the consensus estimate of $10.25 million. Biofrontera had a negative net margin of 25.66% and a negative return on equity of 1,112.63%.

Here are the key takeaways from Biofrontera’s conference call:

• Biofrontera reported Q1 2026 product revenue of $10.1 million, up 17% year over year, driven by a 16% increase in Ameluz tube volume and a price increase implemented in late 2025.
• The new post-transaction cost structure materially improved profitability, with gross margin expanding to about 80% from 62% a year ago and management saying the company is tracking toward its 80%-85% long-term target.
• Cash used in operations was just $70,000 in the quarter, a sharp improvement from $4.1 million in Q1 2025, which management said supports its path to cash flow breakeven this year.
• The clinical/regulatory pipeline advanced on multiple fronts, including FDA acceptance of the supplemental NDA for superficial basal cell carcinoma with a PDUFA date of September 28, 2026, and positive phase III data for AK on the neck, trunk, and extremities supporting a planned sNDA filing in Q3 2026.
• Management also highlighted encouraging phase II acne data and said it expects to discuss a potential phase III program with the FDA later in 2026, while noting ongoing tariff and supply-chain monitoring because all products are imported from Europe.

Biofrontera Stock Performance

Biofrontera stock traded down $0.19 during trading hours on Friday, hitting $0.80. The company had a trading volume of 398,556 shares, compared to its average volume of 201,382. The firm has a market cap of $9.61 million, a PE ratio of -0.82 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.52 and a quick ratio of 1.40. Biofrontera has a one year low of $0.54 and a one year high of $1.19. The firm has a 50-day moving average of $0.97 and a 200 day moving average of $0.90.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. raised its stake in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera comprises 0.3% of Rosalind Advisors Inc.’s holdings, making the stock its 27th largest position. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Biofrontera from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Biofrontera has a consensus rating of “Hold” and a consensus target price of $2.75.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.